Analysed ARVINAS INC (ARVN:NASDAQ) News Sources
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
28-09-2026
yahoo.com
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
01-10-2026
yahoo.com
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
07-10-2026
yahoo.com
What is the current price of ARVINAS INC (ARVN:NASDAQ)?
The current price of ARVINAS INC (ARVN:NASDAQ) is $7.86.
ARVINAS INC (ARVN:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARVINAS INC (ARVN:NASDAQ) since the previous trading day is $-0.04.
ARVINAS INC (ARVN:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARVINAS INC (ARVN:NASDAQ) since the previous trading day is -0.5063%.
What is the most recent average sentiment score for ARVINAS INC (ARVN:NASDAQ)?
The most recent average sentiment score for ARVINAS INC (ARVN:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for ARVINAS INC (ARVN:NASDAQ)?
The most recent sentiment for ARVINAS INC (ARVN:NASDAQ) is .
SEC-8K** Filing Available For ARVINAS INC (ARVN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.